In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Risk factor driven upstream atrial fibrillation therapy improves sinus rhythm maintenance (RACE 3)



Barcelona, Spain – 27 Aug 2017: Risk factor driven upstream rhythm control is effective, feasible and safe in improving maintenance of sinus rhythm in patients with early short lasting atrial fibrillation (AF) and heart failure, according to late-breaking results from the RACE 3 trial presented today in a Hot Line – LBCT Session at ESC Congress. (1) The novel therapy included meticulous treatment of risk factors and change of lifestyle and was superior to conventional guideline recommended rhythm control.

“Atrial fibrillation is the most common sustained cardiac arrhythmia and affects millions of people in Europe,” said principal investigator Dr Michiel Rienstra, cardiologist and clinical director of cardiology at the University Medical Centre Groningen, the Netherlands. “Patients suffer from palpitations, shortness of breath, impaired exercise tolerance, have poor quality of life and are at increased risk of stroke, heart failure or death.”

In most patients, AF is in part caused by comorbidities such as hypertension, heart failure, and obesity. AF is a progressive disease and despite the available medical and interventional therapies, long-term maintenance of normal (sinus) rhythm is cumbersome. AF and its progression are caused by structural remodelling of the left atrium. Upstream rhythm control therapy may modify atrial remodelling and help prevent AF and its progression.

The RACE 3 trial (2) was designed to test the hypothesis that risk factor driven upstream therapy is superior to conventional therapy for maintenance of sinus rhythm at 12 months in patients with early persistent AF and heart failure.

This international, investigator-initiated, multicentre, prospective, open label trial included 250 patients with symptomatic early persistent AF and early mild to moderate heart failure who were scheduled for electrical cardioversion. All patients received causal treatment of AF and heart failure and were then randomly allocated to conventional guideline recommended rhythm control with or without an additional four risk factor driven upstream therapies.

The upstream therapy group received: 1) cardiac rehabilitation including physical activity, dietary restrictions, and regular counselling on drug adherence, exercise maintenance and dietary restrictions; 2) mineralocorticoid receptor antagonists; 3) statins; and 4) angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers.

Upstream therapies started at least three weeks before electrical cardioversion and were continued for 12 months. Every effort was made to optimally titrate all drugs. If AF relapsed, repeat cardioversions, antiarrhythmic drugs and atrial ablation were allowed.

The primary endpoint was the presence of sinus rhythm after one year of follow-up, assessed with continuous seven day Holter monitoring during the last week of the study. Secondary endpoints included atrial size, left ventricular function, exercise capacity, hospitalisations for heart failure and other reasons, mortality, quality of life, and side effects of upstream therapies.

At one year follow-up, sinus rhythm was present in 89 of 119 (75%) patients in the upstream therapy group compared to 79 of 126 (63%) patients in the control group (p=0.021). There was no difference in antiarrhythmic drug use or the number of electrical cardioversions between the two groups.

Dr Rienstra said: “Upstream rhythm control, including meticulous treatment of risk factors and change of lifestyle, is effective, feasible and safe in improving maintenance of sinus rhythm in patients with early short lasting AF and early mild to moderate heart failure. The upstream therapies also improved treatment of cardiovascular risk factors.”

ENDS

Notes to editor

Sources of funding: The trial was funded by grants from the Netherlands Heart Foundation and the Netherlands Heart Institute and by unrestricted educational grants from pharmaceutical and device companies.

Disclosures: The RACE 3 study is supported by grants to the Interuniversity Cardiology Institute Netherlands (now Netherlands Heart Institute) from the Dutch Heart Foundation, Interuniversity Cardiology Institute Netherlands, and University Medical Centre Groningen. In addition, unrestricted grants to the Interuniversity Cardiology Institute Netherlands (now Netherlands Heart Institute) by the following companies; Medtronic, Boehringer Ingelheim, Biotronik, St. Jude Medical (now Abbott), Boston Scientific, AstraZeneca, Sanofi-Aventis, Bayer.

References and notes:
(1) The study “Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure, the RACE 3 study” will be presented during:
• The press conference Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 8:00 to 9:00.
• The session Hot Line - Late Breaking Clinical Trials 1 on Sunday 27 August from 11:00 to 12:30 in Barcelona – Main Auditorium.
(2) Routine versus Aggressive Risk Factor Driven Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure (RACE 3)


ESC Press Office
For more information, please contact the ESC Press Office: press@escardio.org.
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org.

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.